Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data

被引:5
|
作者
Guhra, Michael [1 ]
Thomas, Christine [2 ]
Boedeker, Sebastian [1 ]
Kreisel, Stefan [1 ]
Driessen, Martin [1 ]
Beblo, Thomas [1 ]
Ohrmann, Patricia [3 ]
Toepper, Max [1 ]
机构
[1] Evangel Krankenhaus Bielefeld, Dept Psychiat & Psychotherapy Bethel, D-33617 Bielefeld, Germany
[2] Clin Ctr Stuttgart, Clin Psychiat & Psychotherapy Elderly, D-70374 Stuttgart, Germany
[3] Univ Munster, Dept Psychiat, D-48149 Munster, Germany
关键词
Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Amyloid beta; Tau; Cognition; Memory; Executive function; CEREBROSPINAL-FLUID LEVELS; EXECUTIVE FUNCTION; TAU-PROTEIN; HYPOTHETICAL MODEL; DYNAMIC BIOMARKERS; FALSE RECOGNITION; OLDER-ADULTS; IMPAIRMENT; MEMORY; DEMENTIA;
D O I
10.1016/j.exger.2015.11.008
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: Memory and executive deficits are important cognitive markers of Alzheimer's disease (AD). Moreover, in the past decade, cerebrospinal fluid (CSF) biomarkers have been increasingly utilized in clinical practice. Both cognitive and CSF markers can be used to differentiate between AD patients and healthy seniors with high diagnostic accuracy. However, the extent to which performance on specific mnemonic or executive tasks enables reliable estimations of the concentrations of different CSF markers and their ratios remains unclear. Methods: To address the above issues, we examined the association between neuropsychological data and CSF biomarkers in 51 AD patients using hierarchical multiple regression analyses. In the first step of these analyses, age, education and sex were entered as predictors to control for possible confounding effects. In the second step, data from a neuropsychological test battery assessing episodic memory, semantic memory and executive functioning were included to determine whether these variables significantly increased (compared to step 1) the explained variance in A beta(42) concentration, p-tau concentration, t-tau concentration, A beta(42)/t-tau ratio, and A beta(42)/A beta(40) ratio. Results: The different models explained 52% of the variance in A beta(42)/t-tau ratio, 27% of the variance in A beta(42) concentration, and 28% of the variance in t-tau concentration. In particular, A beta(42)/t-tau ratio was associated with verbal recognition and code shifting, with A beta(42) being related to verbal recognition and t-tau being related to code shifting. By contrast, the inclusion of neuropsychological data did not allow reliable estimations of A beta(42)/A beta(40) ratio or p-tau concentration. Conclusion: Our results showed that strong associations exist between the cognitive key symptoms of AD and the concentrations and ratios of specific CSF markers. In addition, we revealed a specific combination of neuropsychological tests that may facilitate reliable estimations of CSF concentrations, thereby providing important diagnostic information for non-invasive early AD detection. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:107 / 113
页数:7
相关论文
共 50 条
  • [1] Regional relationships between CSF VEGF levels and Alzheimer's disease brain biomarkers and cognition
    Tubi, Meral A.
    Kothapalli, Deydeep
    Hapenney, Matthew
    Feingold, Franklin W.
    Mack, Wendy J.
    King, Kevin S.
    Thompson, Paul M.
    Braskie, Meredith N.
    NEUROBIOLOGY OF AGING, 2021, 105 : 241 - 251
  • [2] Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting
    Dumurgier, Julien
    Vercruysse, Olivier
    Paquet, Claire
    Bombois, Stephanie
    Chaulet, Chloe
    Laplanche, Jean-Louis
    Peoc'h, Katell
    Schraen, Susanna
    Pasquier, Florence
    Touchon, Jacques
    Hugon, Jacques
    Lehmann, Sylvain
    Gabelle, Audrey
    ALZHEIMERS & DEMENTIA, 2013, 9 (04) : 406 - 413
  • [3] Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice
    Koric, L.
    Felician, O.
    Ceccaldi, M.
    REVUE NEUROLOGIQUE, 2011, 167 (6-7) : 474 - 484
  • [4] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [5] Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort
    Radanovic, Marcia
    Oshiro, Carlos A.
    Freitas, Thiago Q.
    Talib, Leda L.
    Forlenza, Orestes V.
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (06) : 479 - 484
  • [6] CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease
    Warmenhoven, Noelle
    Sanchez-Benavides, Gonzalo
    Gonzalez-Escalante, Armand
    Mila-Aloma, Marta
    Shekari, Mahnaz
    Lopez-Martos, David
    Ortiz-Romero, Paula
    Kollmorgen, Gwendlyn
    Quijano-Rubio, Clara
    Minguillon, Carolina
    Domingo Gispert, Juan
    Vilor-Tejedor, Natalia
    Arenaza-Urquijo, Eider
    Palpatzis, Eleni
    Ashton, Nicholas J.
    Zetterberg, Henrik
    Blennow, Kaj
    Suarez-Calvet, Marc
    Grau-Rivera, Oriol
    ALZHEIMERS & DEMENTIA, 2024, 20 (09) : 5819 - 5832
  • [7] Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease
    Watson, GS
    Bernhardt, T
    Reger, MA
    Cholerton, BA
    Baker, LD
    Peskind, ER
    Asthana, S
    Plymate, SR
    Frölich, L
    Craft, S
    NEUROBIOLOGY OF AGING, 2006, 27 (01) : 38 - 41
  • [8] Clinical indications for analysis of Alzheimer's disease CSF biomarkers
    Engelborghs, S.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 709 - 714
  • [9] Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF A,B42 moderates the association between insulin resistance and increased CSF tau levels
    Woodfield, Amy
    Porter, Tenielle
    Gilani, Israa
    Noordin, Siti
    Li, Qiao-Xin
    Collins, Steven
    Martins, Ralph N.
    Maruff, Paul
    Masters, Colin L.
    Rowe, Christopher C.
    Villemagne, Victor L.
    Dore, Vincent
    Newsholme, Philip
    Laws, Simon M.
    Verdile, Giuseppe
    NEUROBIOLOGY OF AGING, 2022, 114 : 38 - 48
  • [10] Alzheimer’s disease CSF biomarkers: clinical indications and rational use
    Ellis Niemantsverdriet
    Sara Valckx
    Maria Bjerke
    Sebastiaan Engelborghs
    Acta Neurologica Belgica, 2017, 117 : 591 - 602